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Clear cell renal cell carcinoma (ccRCC), the most common subtype of RCC, is characterized by high metastasis potential and
strong resistance to traditional therapies, resulting in a poor ﬁve-year survival rate of patients. Several therapies targeted to VEGF
pathway for advanced RCC have been developed, however, it still needs to discover new therapeutic targets for treating RCC.
Genome-widegeneexpressionanalyseshavebeenbroadlyusedtoidentifyunknownmolecularmechanismsofcancerprogression.
Recently, we applied the oligo-capping method to construct the full-length cDNA libraries of ccRCC and adjacent normal kidney,
and analyzed the gene expression proﬁles by high-throughput sequencing. This paper presents a review for recent ﬁndings on
therapeutic potential of MYC pathway and nicotinamide N-methyltransferase for the treatment of RCC.
1.Introduction
Renal cell carcinoma (RCC) represents 3% of all human
malignancies worldwide with an increasing incidence and
accountsfor85%ofrenalcancers,resultingincloseto78,000
deaths annually [1–5]. The most common subtype, clear cell
RCC (ccRCC), which originates from the proximal tubule
epithelium, is mostly sporadic, unilateral, and unifocal [6].
RCC cells have a poor response to traditional therapies,
such as the chemotherapy, hormonal therapy, and radiation
therapy [7–10]. These properties result in a poor prognosis
and low ﬁve-year survival rate of RCC patients.
Surgery remains to be the main therapeutics for treat-
ment of RCC [11]. It has been demonstrated that the
activation of hypoxia-inducible factor-α (HIF-α)t u r n so n
the genes, such as VEGF and PDGF, which are responsible
for the progression of ccRCC, providing potential targets for
advanced ccRCC [12].
Gene expression analysis appears to be an important tool
for studying cancer pathogenesis and progression. Markers
related to tumor proliferation, growth, angiogenesis, and
loss of cell adhesion have been evaluated for their potential
as prognostic factors. Numerous reports have investigated
the diﬀerential gene expression proﬁle between normal
and tumor tissues using the high-throughput technologies,
including cDNA microarray, cDNA subtraction, and serial
analysis of gene expression [13–15]. Many studies have
applied these methods to analyze the genome-wide changes
in ccRCC, providing speciﬁc gene expression signature,
the potential biomarkers, and prognostic factors [16–21],
whereas Lenburg et al. pointed out a diverse gene expression
results by microarray method published previously [22].
Recently, two international projects, The Cancer Genome
Atlas (TCGA) and International Cancer Genome Consor-
tium (ICGC), have been organized to provide the platform
for the integration and comparison of cancer genomic
abnormalities identiﬁed by independent research groups
[23–25].
The oligo-capping method developed by Dr. Suzuki
and Dr. Sugano at the Institute of Medical Science of
Tokyo University was applied to construct the full-length
enriched cDNA library for the analysis of transcriptional
start sites of genes [26, 27]. Yamada et al. utilized the oligo-
capping method to explore gene expression proﬁles of hepa-
toblastomas and the corresponding normal livers and iden-
tify a poor-prognostic indicator for hepatoblastomas [28].2 Journal of Oncology
To investigate the diﬀerentially expressed genes in ccRCC,
the full-length enriched cDNA libraries of ccRCC and
normal kidney tissues were constructed and sequenced. We
identiﬁed 383 diﬀerentially expressed genes, and further
conﬁrmedthediﬀerential expressionof 20ccRCC-associated
genes, which have not been reported to be dysregulated in
ccRCC. By functional network analysis using 383 diﬀeren-
tially expressed genes, MYC pathway was identiﬁed to be
activated in neoplastic disease [29]. By using MYC siRNA,
the importance of MYC was further demonstrated in ccRCC
cells.
Additionally,nicotinamideN-methyltransferase(NNMT)
was identiﬁed as the ninth of 201 upregulated genes with
65.2-fold increase in full-length cDNA-enriched libraries
of ccRCC tissues. We showed that NNMT contributes to
MMP-2expressiontoinducecellinvasivenessviaPI3K/AKT/
SP1 pathway, suggesting NNMT as a novel invasive-related
gene for ccRCC. Our results elucidate the novel functions
of NNMT in ccRCC and suggest that NNMT could be
considered as a potential therapeutic target of ccRCC.
2. Gene ExpressionProﬁles of ccRCC and
Normal Kidney
To construct the full-length enriched cDNA libraries from
two tissues of ccRCC (Grade II/Stage I; Grade II/Stage
II) and adjacent normal kidney, the oligo-capping method
developed by Y. Suzuki and S. Sugano was performed.
We successfully sequenced 19,425 and 12,400 colonies of
ccRCC and normal kidney cDNA libraries, respectively. The
sequencing results were blasted to the UniGene database
of NCBI using the BLAST program. The blast result with
the score more than 200 was denoted as a gene, and a
total of 4,356 and 3,055 genes were identiﬁed in the full-
length enriched cDNA libraries from ccRCC and normal
kidney tissues, respectively. The gene expression patterns of
ccRCCand normal kidney werefurther compared to identify
diﬀerentiallyexpressedgenes.Bythedeﬁnitionthatthegenes
with the colony number in ccRCC three-fold higher or lower
than that in normal kidney were considered as the ccRCC-
associated genes, 201-upregulated and 182-downregulated
genes were identiﬁed [30].
3.ClassiﬁcationofccRCC-AssociatedGenesby
Cellular Function
The diﬀerentially expressed genes in ccRCC were classiﬁed
into groups by their cellular functions according to gene
ontology (GO) term in NCBI [30]. We observed that many
metabolism-related genes were diﬀerentially expressed in
ccRCC, such as NNMT, lysyl oxidase, transglutaminase 2,
heme oxygenase 1, argininosuccinate synthetase, alcohol
dehydrogenase 6, and phosphoenolpyruvate carboxykinase
1, indicating that the ccRCC cells might lose their nor-
mal functions as the kidney cells, and the metabolism-
related genes might play a role in cancer progression.
Additionally, the diﬀerential expression of several signal
transduction-related genes was found, including secreted
frizzled-related protein 1, insulin-like growth factor-binding
protein 3, regulator of G-protein signaling 1, and frizzled-
related protein, implying the activation of signaling path-
ways associated with the process of carcinogenesis. The
genes involved in cellular proliferation were also found
to be dysregulated. For instance, transforming growth
factor (beta-induced), CD74 antigen, alpha-2-glycoprotein
1, inhibin, cyclin D1, and cell division cycle 42 were
diﬀerentially expressed. The results might support the high
proliferation ability of ccRCC cells. Interestingly, we also
observed the altered expression of genes which function
as cytoskeleton assembly, protease or protease inhibitor,
such as gelsolin, MMP-2, cathepsin S, kininogen 1, alpha-
1 antiproteinase member 5 and tissue inhibitor of metallo-
proteinase 3, providing the strong invasive activity of ccRCC
cells.
4. Differential Expressionof the Novel
ccRCC-Associated GenesinccRCC
The diﬀerential expression of the ccRCC-associated genes,
which have not been reported to be dysregulated in ccRCC,
was further studied in ccRCC tissue pairs by Q-PCR analysis
(Table 1). Interestingly, the expression of the modulators of
the Wnt signaling pathway, secreted frizzled-related protein
2 and 4, were signiﬁcantly upregulated 34.9-, and 4.3-fold,
respectively. In addition, the detoxiﬁcation-related gene,
glutathione S-transferase A3 was found to be signiﬁcantly
downregulated in ccRCC, indicating an elevated oxidative
stress in ccRCC tissues. The overexpression of secreted
proteinacidrich incysteine(SPARC)hasbeendemonstrated
in various cancers. Previous reports have shown that SPARC
is involved in tumor development [31, 32], and in this study
we also observed the upregulation of SPARC expression in
ccRCC, suggesting the important role of SPARC in ccRCC
(Table 1).
5.ActivationofMYCPathwayinccRCC
To identify the deregulated cellular pathways in ccRCC,
functional network analysis was performed with the 383
ccRCC-associated genes by using Ingenuity Pathway Anal-
ysis, which has been used to identify signiﬁcant pathways
related to tumorigenesis in several tumors [33, 34]. The list
oftheccRCC-associatedgeneswasuploadedtotheIngenuity
system and used as focus genes to produce the biological
networks. The P values were calculated to represent the
statistical signiﬁcance that the focus genes in a network
are randomly found together. The results of Ingenuity
Pathway Analysis revealed that 17 networks were statistically
signiﬁcant and contained more than 10 ccRCC-associated
genes. The top-ranking biological functions of each network
were assigned according to Ingenuity Pathways Knowledge
Base. The ﬁve biological networks with the highest score
were found to be functionally related to cancer progression,
such as cell cycle, cellular growth, or cellular movement
(Table 2).Journal of Oncology 3
Table 1: Diﬀerential expression of ccRCC-associated genes in ccRCC.
Unigene number Gene symbol Gene name Location Average fold change Percentage (%)
Hs.481022 SFRP2 Secreted frizzled-related
protein 2 4q31.3 34.9 50
Hs.511883 ZNF114 Zinc ﬁnger protein 114 19q13.33 9.2 32
Hs.164021 CXCL6
chemokine (C-X-C motif)
ligand 6 (granulocyte
chemotactic protein 2)
4q21 5.0 39
Hs.597524 CDC42 Cell division cycle 42 (GTP
binding protein, 25kDa) 1p36.1 6.0 48
Hs.436367 LAMA3 Laminin, alpha 3 18q11.2 5.7 43
Hs.128453 FRZB Frizzled-related protein 2qter 6.2 61
Hs.181301 CTSS Cathepsin S 1q21 8.3 89
Hs.416007 SFRP4 Secreted frizzled-related
protein 4 7p14.1 4.3 50
Hs.111779 SPARC Secreted protein, acidic,
cysteine-rich (osteonectin) 5q31.3–q32 4.3 75
Hs.77269 GNAI2
Guanine nucleotide
binding protein (G
protein), alpha inhibiting
activity polypeptide 2
3p21 3.4 50
Hs.480653 ANXA5 Annexin A5 4q28–q32 3.1 36
Hs.168718 AFM Afamin 4q11–q13 −1020.2 98
Hs.102484 GSTA3 Glutathione S-transferase
A3 6p12.1 −72.8 70
Hs.110675 APOE Apolipoprotein E 19q13.2 −6.4 61
Hs.527971 NES Nestin 1q23.1 −6.3 48
Hs.9029 KRT23 Keratin 23 (histone
deacetylase inducible) 17q21.2 −5.5 50
Hs.54415 CSN3 Casein kappa 4q21.1 −3.7 34
Hs.632294 ZNF38 Zinc ﬁnger protein 38 7q22.1 −2.3 41
Hs.389996 CHCHD2
Coiled-coil-helix-coiled-
coil-helix domain
containing 2
7p11.2 −2.0 36
Hs.458358 TSPYL1 TSPY-like 1 6q22-q23 −2.3 50
Interestingly, the top functional network with the highest
score was composed of 35 diﬀerentially expressed genes
and was assembled around the oncogene, MYC, with a
set of MYC-target genes. The crucial role of MYC has
been demonstrated in numerous kinds of human tumors
and the regulation of cancer-related gene expression [35].
The upregulation or ampliﬁcation of MYC in ccRCC has
been previously reported [36–39]. Recent reports showed
that HIF-2α promotes the transcriptional activity of MYC,
whereas HIF-1 suppresses it [40, 41]. We further identiﬁed
the MYC transcriptional targets among the 383 diﬀerentially
expressed genes in ccRCC by using Ingenuity Pathways
Knowledge Base. The diﬀerentially expressed genes with the
connection to MYC labeled as expression (E), transcription
(T), or protein-DNA interaction (PD) were considered as
the MYC-target genes. As shown in Figure 1,3 7d i ﬀeren-
tially expressed genes were found to be the MYC-target
genes, suggesting that the MYC pathway members may be
activated in ccRCC tissues, indicating that MYC pathway is
activated and plays an important role in carcinogenesis of
ccRCC.
Furthermore, the upregulated expression of MYC was
examined in 44 ccRCC tissue pairs by Q-PCR analysis.
The average expression level of MYC in ccRCC tissues
was signiﬁcantly higher than that in normal kidney tissues.
The results of immunohistochemical staining analysis also
demonstrated that 24 (96%) of 25 ccRCC tissues showed
the positive staining for MYC, including 15 cases with
3+ staining, 7 cases with 2+ staining, and 2 cases with
1+ staining, but negative staining for nonneoplastic renal
tubules. The expression levels of MYC were also examined
in 786O, 769P, A498, ACHN, and Caki-1 cells, which were
derived from patients with ccRCC, and the results revealed
that all of these ccRCC cell lines displayed a signiﬁcant
upregulation of MYC as compared with that of a pool of 5
normal tissues. These results suggest that the expression of
MYC is markedly increased in ccRCC tissues and cell lines
[30].4 Journal of Oncology
Table 2: Top 5 functional networks of 383 diﬀerentially expressed genes in ccRCC.
1
ANXA1,ANXA2, ARL6IP1,BRD2, CTSB, DBI, FBL,HNRPU, LAMP2,
LDHA,LGMN, MAZ, MIF, MYC, NAP1L1, NDRG1, NPM1 (includes EG:
4869), PABPC1,PCBP2, PGK1, PRDX1, PRMT1,PTBP1, RBMS1, RPL7,
RPL22, RPL26, RPL35, RPS3A, RPS4X, SERIN C3,SPP1,SU CL A2,
TAGLN2, TMSB4X
55 35 Protein synthesis, cellular assembly and
organization, cancer
2
14-3-3, ALDOC,CCNB1,CCNE1,CD74, COL1A2, CTSS,CXCR4,
DYRK1A, E3 RING, FBXO18, H3F3A (includes EG: 3020), Histone h3,
Hsp70,Hsp90, HSP90AB1,MAP3K2,MGMT, MLL, NME1, NOS3,
PGAM1,PRMT5,PTGES3 (includes EG: 10728),RNA polymerase II,
SAP18,SET, SKP1A, SMARCE1(includes EG: 6605),SNRPD2, ST13,
TCEB2, VHL, VIM, YWHAE
40 29 Cancer, cell cycle, cellular compromise
3
AGT, Akt, ANXA7, ATF6, BCL2,CA2,CALM1, Calmodulin, CANX,Ck2,
CSF1R,DUSP1, EGFR,EGR1,ENPEP, GRB10,HSPD1, KNG1 (includes
EG: 3827), LGALS1, LGALS3,LTF, Mapk, MET,MHC Class I, P38 MAPK,
PIGR, PMP22, Ras, RTN4, SNX4, SQSTM1, SRI, STAT1, WT1, XBP1
37 28
Cellular development, cellular growth
and proliferation, connective tissue
development and function
4
Ap1, ARF1,ARFIP2, ATF4,CCND1, CCND3,Creb, Cyclin D, DDX5,
EID1, Fibrin, ID2,IGF2, Igfbp, IGFBP2,IGFBP3,KLK5 (includes EG:
25818), Mmp, MMP2,MMP7, MMP24, PCK1, PCK2,PCNA,PEPCK,
PLG,Rb, RFC1, SERPINA1,SPARC,SRA1 (includes EG: 10011), TIMP3,
Vegf, VEGFA, VTN
33 26 Cancer, cellular movement, reproductive
system disease
5
ANGPTL4,ASS1, BNIP3L, ELA2, EREG, ESM1,F10, GPX4, HADHA,
HADHB,HGF, HIF1A, HNF4A, HSPA5,IFITM3,IGF2,IGFBP3,LIPA,
MET,MMP2,NOS3, NR2F1, PHC2, PKM2, PLAUR, POGZ, RNF4,
SLC16A4, SLC2A1, SP1, TERT, TFPI2,TRPS1, Vegf, VEGFA
20 19
Cancer, tumor morphology,
cardiovascular system development and
function
The score represents the negative log of P value that indicates the likelihood of the focus genes in a network being found together due to chance. The number
of focus genes reﬂects number of the diﬀerentially expressed genes of ccRCC in a network generated by IPA. (Bold): upregulated genes in ccRCC. (Bold and
italic): downregulated genes in ccRCC. (Italic): group or complex. (Standard text): nonfocus genes not included in the 383 diﬀerentially expressed genes of
ccRCC.
Table 3: Expression levels of MYC-target genes in ccRCC and adjacent normal tissues.
Gene name Normal kidney versus ccRCC† (P value‡)
Correlation coeﬃcient with MYC
expression level of ccRCC tissues
(P value)§
BCL2 −6.58 ±0.12 versus −3.84 ±0.17 (<0.001) 0.45 (0.002)∗
CCND1 −4.45 ±0.14 versus −2.62 ±0.18 (<0.001) 0.31 (0.038)∗
PCNA −5.78 ±0.14 versus −4.76 ±0.13 (<0.001) 0.33 (0.038)∗
PGK1 −3.40 ±0.18 versus −2.70 ±0.14 (<0.001) 0.42 (0.004)∗
VEGFA −3.93 ±0.30 versus −1.23 ±0.21 (<0.001) 0.36 (0.016)∗
†Expression levels of MYC-target genes (−ΔCtGENE-TPT1 values) measured by Q-PCR in 44 tissues were represented as mean ± SE.
‡Signiﬁcance of diﬀerence was determined by paired-samples Student’s t test.
§Correlation between the expression levels of MYC and MYC-target genes in ccRCC tissues was determined by Pearson correlation method.
∗P<0.05 was considered statistically signiﬁcant.
To investigate whether the expression of MYC path-
way signature is enhanced due to MYC activation, the
expression levels of the MYC-target genes, BCL2, CCND1,
PCNA, PGK1, and VEGFA, which have been reported to
be functionally related to cancer progression [42, 43], were
further investigated in 44 ccRCC tissues by Q-PCR analysis.
As shown in Table 3, the signiﬁcant upregulation of these
MYCpathwaymemberswasdemonstrated.Byanalysisofthe
Pearson correlation method, we observed that the expression
levels of BCL2, CCND1, PCNA, PGK1, and VEGFA were
correlated with the levels of MYC in the tumor tissues
of ccRCC (Table 3). These results indicate that the MYC
pathway signature is activated and is associated with MYC
upregulation in ccRCC tissues.
6. Suppressingthe Expressionof
MYC-Target GenesbyMYC siRNA
We have demonstrated the correlation between the expres-
sion levels of MYC and the MYC-target genes in ccRCC
tissues (Table 3). Therefore, whether the expression of the
MYC-target genes is suppressed by the knockdown of MYC
expression in ccRCC cells were investigated. The results of
Q-PCR analysis revealed that treatment of MYC-speciﬁc
siRNA signiﬁcantly reduced expression levels of MYC-target
genes BCL2, CCND1, PGK1, PCNA, and VEGFA in 769P
cells [30]. It has been demonstrated that MYC is able to
bind to speciﬁc DNA sequences (E-box motif, CACGTG) to
function as a transcription factor [31]. Therefore, whetherJournal of Oncology 5
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MYC could be directly recruited to the promoter regions
of these MYC-target genes was studied. The potential E-
box sites on the promoters of BCL2, CCND1, and PCNA
were identiﬁed by blasting the sequence, CACGTG, with the
potential promoter regions of BCL2, CCND1, and PCNA,
and the primer pairs to speciﬁcally amplify the promoter
regions containing the potential E-box sites were generated
using Beacon Designer 4 program. The primers to amplify
the E-box sites in the promoters of PGK1 and VEGFA
have been described in previous studies. The Chromatin
immunoprecipitation (ChIP) assay was carried out using
these primers to amplify the potential MYC-binding regions
in BCL2, CCND1, PCNA, PGK1, and VEGFA promoters.
The endogenous MYC was observed to bind onto the
promoter regions of BCL2, CCND1, PCNA, PGK1, and
VEGFA [30]. These results indicate that MYC expression is
able to enhance the expression levels of MYC-target genes by
binding to their promoters in ccRCC cells.6 Journal of Oncology
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Figure 2: Overexpression of NNMT in ccRCC tissues. (a) mRNA
expression levels of NNMT of 33 tissue pairs of ccRCC mea-
sured by Q-PCR analysis. Expression levels are represented by
−ΔCtNNMT-TPT1 values. Each dot represents one tissue sample, and
horizontal bars show mean values. P values are determined using
a paired-samples Student’s t test. (b) Western blot analysis to
determine expression levels of NNMT protein in 10 ccRCC tissue
pairs. N and T represent lysates from normal and tumor parts,
respectively. Actin was used as a loading control.
Previous studies have demonstrated that MYC plays a
role in cellular transformation [29]. To address whether the
expression of MYC is required for the malignant ability of
ccRCCcells,theeﬀectsoftheknockdown ofMYCexpression
by RNAi technique was investigated in ccRCC cell lines, 769P
and Caki-1 cells. As displayed in Figure 4(a), the expression
level of MYC in 769P and Caki-1 cells were markedly
suppressed by MYC-speciﬁc siRNA in a dose-dependent
manner. The results of MTT assay revealed that the prolifer-
ation rate of 769P and Caki-1 cells was signiﬁcantly reduced
by knockdown of MYC expression in a dose-dependent
manner (Figure 4(b)). Additionally, treatment with 20nM of
MYC-speciﬁc siRNA dramatically suppressed 95% and 91%
of anchorage-independent growth ability in 769P cells and
Caki-1 cells as shown by soft agar assay, respectively [30].
These results indicate that RNAi-mediated knockdown of
MYC strongly suppresses the proliferation and anchorage-
independent growth of ccRCC cells.
It has been shown that MYC promotes cell cycle pro-
gression of cancer cells to enhance an uncontrolled cellular
proliferation in various malignances [43]. Therefore, we fur-
ther investigate whether the knockdown of MYC expression
has the capacity of arresting cell cycle progression in ccRCC
cells. Cell cycle distribution of 769P cells was analyzed by
PI staining and ﬂow cytometry analysis after treated with
MYC siRNA. The results showed a signiﬁcant increase of
G0/G1 phase population of MYC siRNA-transfected cells as
comparedwiththecontrolcells.Additionally,thepopulation
in the process of DNA synthesis (S phase) was markedly
decreased in 769P cells treated with MYC-speciﬁc siRNA
[30]. These results show that a reduction of MYC expression
disrupted the G1/S phase transition of 769P cells.
7. Overexpression of NNMT in ccRCC Tissues
Among these diﬀerentially expressed genes identiﬁed by
analysis of full-length cDNA libraries in ccRCC, NNMT was
one of the most upregulated genes with 65.2-fold overex-
pression. Previous studies have demonstrated that NNMT is
overexpressed in ccRCC tissues and has the potential to be
ac c R C Cb i o m a r k e r[ 44, 45]. To investigate whether NNMT
is overexpressed in ccRCC tissue pairs, Q-PCR analysis was
used to examine the mRNA levels of NNMT in these tissue
pairs. The results showed that the expression of NNMT in
27 of 33 ccRCC tumors was highly upregulated (T/N > 3.0)
by an average of 52.8-fold compared with that in adjacent
normal kidney tissues (Figure 2(a)). The results of Western
blot analysis also demonstrated a marked increase in NNMT
p r o t e i nl e v e l si nc c R C Ct i s s u e s( Figure 2(b)). These results
suggest that NNMT is overexpressed in ccRCC, and it was
also reported that the overexpression of NNMT was found
in colorectal cancer, papilloma thyroid cancer, and gastric
cancer [46–48].
8. Identiﬁcation of the Potential
Role of NNMT in ccRCC
Interestingly, Wu et al. recently demonstrated that a corre-
lation between NNMT and cancer cell migration has been
reported in bladder cancer [49]. We further investigated
the expression levels of genes related to cell invasiveness
in HEK293/NNMT cells using Q-PCR analysis, and MMP-
2 expression was found to be enhanced by NNMT over-
expression. As shown in Figure 3(a), MMP-2 expression
of HEK293/NNMT cells was enhanced 4-fold compared
with that of HEK293/vector cells. The results of gelatin
zymography and western blot analyses demonstrated a sig-
niﬁcant increase of MMP-2 protein level in HEK293/NNMT
cells (Figure 3(b)). Moreover, by treating siRNA speciﬁc to
NNMT gene, the expression of NNMT was signiﬁcantly
suppressed and was accompanied by a reduction of MMP-2
expression in HEK293/NNMT cells (Figure 3(c)).
The eﬀects of silenced NNMT expression on the MMP-
2 expression were further investigated in ccRCC cell lines.
Figure 4(a) indicated that 786O and Caki-1 cells (invasive
ccRCC cell lines) had a higher NNMT and MMP-2 expres-
sion than those of 769P and Caki-2 cells (primary ccRCC
cell lines). The results of siRNA treatment showed that the
knockdown ofNNMTexpressionresultedinthesuppression
ofMMP-2expressionin786OandCaki-1cells(Figure 4(b)).
These results suggest that NNMT expression is involved in
MMP-2 expression.Journal of Oncology 7
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Figure 3: Eﬀects of NNMT overexpression on the expression of MMP-2. (a) The expression levels of MMP-2 mRNA in HEK293/vector
(control) and HEK293/NNMT cells were determined by Q-PCR and normalized to GAPDH. Data are presented as the mean of triplicate
replications. S.D. is indicated by error bars. ∗∗P<0.001 versus control cells. (b) Gelatin zymography assay was used to examine the MMP-2
activity in conditioned media, and western blot analysis to detect MMP-2 and NNMT in cell lysates from HEK293 cells with or without
NNMT expression. (c) HEK293/vector and HEK293/NNMT cells were transfected with 40μmol/L of NNMT siRNA or control siRNA.
Q-PCR (upper) gelatin zymography and Western blot analyses (lower) were performed to determine the expression levels of NNMT and
MMP-2. Q-PCR data are presented as the mean of triplicate replications. S.D. is indicated by error bars. ∗∗P<0.001 versus control cells.
Actin was used as loading control.8 Journal of Oncology
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Figure 4: Eﬀects of NNMT siRNA on MMP-2 expression in ccRCC cells. (a) Expression levels of MMP-2 and NNMT in ccRCC cell lines.
Q-PCR was performed to determine MMP-2 and NNMT expression in ccRCC cell lines, 796P, 786O, Caki-2, and Caki-1. GAPDH was used
asaninternalcontrol.(b)786OandCaki-1cellsweretransfectedwith40μmol/LofNNMTsiRNAorcontrolsiRNA.Q-PCR(upper),gelatin
zymography and western blot analyses (lower) were performed to determine the expression levels of NNMT and MMP-2. Q-PCR data are
presented as the mean of triplicate replications. S.D. is indicated by error bars. ∗∗P<0.001 versus control cells. Actin was used as a loading
control.
0
−2
−4
−6
−8
−10
−12 −10 −8 −6 −4 −2
r = 0.47, P<0.01
−
Δ
C
t
(
M
M
P
-
2
-
T
P
T
1
)
−ΔCt(NNMT-TPT1)
(a)
NNMT MMP-2
Case 1
Case 2
(b)
Figure 5: Correlation between the expression levels of NNMT and MMP-2 in ccRCC tissues. (a) Expression levels of NNMT and MMP-2 in
33 ccRCC tissues were dotted by using the −ΔCt values, and the correlation between the expression of NNMT and MMP-2 was analyzed by
the Pearson correlation method (r = 0.47, P<0.01). (b) Immunohistochemistry analysis was used to detect NNMT and MMP-2 in ccRCC
tissue sections. The representative cases with a positive (case 1) or negative (case 2) immunostaining of NNMT and MMP-2 are shown.
Arrow indicates the cytoplasm immunostaining of NNMT and MMP-2. Photos were taken under 100x magniﬁcation.Journal of Oncology 9
HEK293/NNMT
R
e
l
a
t
i
v
e
 
l
u
c
i
f
e
r
a
s
e
 
a
c
t
i
v
i
t
y
 
(
f
o
l
d
)
LY294002
PD98059
SB202190
SP600125
+
+
+
+
−
−
−
−
−
−−
−−−
−−−
−−
−
−
−
−
−
3
2
1
0
∗∗
HEK293/vector
(a)
HEK293/NNMT
R
e
l
a
t
i
v
e
 
M
M
P
-
2
 
e
x
p
r
e
s
s
i
o
n
 
(
f
o
l
d
)
LY294002 (µmol/L)
AKT inhibitor IV (µmol/L)
1.2
1
0.8
0.6
0.4
0.2
0
10 20 20 10 10 20
1.25 2.5 1.25 2.5 1.25 2.5
786O Caki-1
∗∗
∗∗
∗∗
∗∗
∗∗
∗∗
∗
∗
∗
∗
∗
∗
−− −−
−− −
−− −
−−−
−−
− − −
(b)
Figure 6: Signaling pathway involved in NNMT-mediated MMP-2 expression. (a) Various signaling pathway inhibitors were used to treat
HEK293/NNMT cells transfected with full-length MMP-2 promoter plasmid and control reporter plasmid. The MMP-2 promoter activity
wasmeasuredbyluciferasereporterassay.Dataarepresentedasthemeanoftriplicatereplications.S.D.isindicatedbyerrorbars. ∗∗P<0.001
versusuntreatedHEK293/NNMTcells.(b)HEK293/NNMT,786OandCaki-1cellsweretreatedwithLY294002orAKTinhibitorIVfor18h,
and the expression of MMP-2 was measured by Q-PCR. Data are presented as the mean of triplicate replications. S.D. is indicated by error
bars. ∗P<0.05; ∗∗P<0.001 versus untreated cells.
Moreover, we examined whether the expression of
NNMT and MMP-2 was correlated in ccRCC tissues, and the
results indicated a positive correlation between the mRNA
levels of NNMT and MMP-2 in ccRCC tissues based on
the statistical analysis using the Pearson correlation method
(r = 0.47). The results of immunohistochemistry analysis
also demonstrated that NNMT was overexpressed in 76%
of ccRCC tissues, whereas the expression of MMP-2 was
upregulated in 58% of ccRCC tissues. By the analysis of
the Pearson’s chi-square test, the expression of NNMT
and MMP-2 was observed to be signiﬁcantly correlated in
ccRCC tissues (Figure 5(a)), and the representative cases
were shown in Figure 5(b). These results indicate that the
expression of NNMT and MMP-2 is correlated in ccRCC
tissues.
9. PI3K/AKT/SP1 PathwayIs Involvedin
NNMT-Mediated MMP-2 Expression
To identify which signaling pathway may participate in
MMP-2 expression induced by NNMT, the signaling-
pathway inhibitors, HEK293/NNMT cells were treated with
the signaling-pathway inhibitors LY294002 (PI3K), PD98059
(ERK1/2), SB203580 (p38), and SP600125 (JNK), and
then luciferase reporter assay was performed to measure
the transcriptional activity of the full-length MMP-2 pro-
moter. The results showed that treating with LY294002,
but not SB203580, PD98059, and SP600125, markedly
suppressed MMP-2 promoter activity in HEK293/NNMT
cells (Figure 6(a)). Additionally, the expression levels of
MMP-2 in HEK293/NNMT, 786O, and Caki-1 cells were
signiﬁcantly reduced by the treatment of LY294002 and
AKT inhibitor IV (Figure 6(b)), indicating the impor-
tance of PI3K/AKT pathway on NNMT-mediated MMP-2
expression.
To study the crucial region in the MMP-2 promoter
responding to NNMT-mediated MMP-2 expression, a
1,716kb genomic fragment containing the upstream region
of MMP-2 gene (WT) and a serial of successive 5  deletions
( D 1t oD 7c o n s t r u c t s )w e r ec l o n e di n t op G L 3l u c i f e r a s e
reporter vector [50]. pGL3-MMP-2 promoter plasmid and
pGL3 control reporter plasmid were transfected into cells,
and the promoter activities were examined using the
luciferase reporter assay. As shown in Figure 7(a),a2 - f o l d
increase of the transcriptional activity of the full-length
MMP-2 promoter in HEK293/NNMT cells was observed
than that in control cells. Additionally, about 4-fold decrease
of transcription activities of D6 and D7 mutants, but not
D1-D5 mutants, was found as compared with that of the
full-length MMP-2 promoter in HEK293/NNMT cells. It
indicates that the SP1-binding elements in MMP-2 promoter
are required for NNMT-mediated MMP-2 expression. The
importance of SP1-binding elements was further examined
by using a MMP-2 promoter construct with mutated SP1-
binding elements (bp −94 to −64). The results of luciferase10 Journal of Oncology
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Figure 7: Role of SP1-binding elements in MMP-2 transcriptional activity. (a) The diagrams of the reporter constructs of full-length or
various deletion mutants of MMP-2 promoter (D1–D7) are depicted on the left. The solid lines are the regions cloned upstream of the
luciferase gene in the pGL3 luciferase reporter vector. The luciferase activity of cell extracts was analyzed by luciferase reporter assay. Data
are presented as the mean of triplicate replications. S.D. is indicated by error bars. ∗∗P<0.001 versus HEK293/NNMT cells transfected with
full-length MMP-2 promoter. (b) Eﬀects of site-speciﬁc mutation of the two putative SP1-binding sites on MMP-2 promoter activity were
examined by luciferase reporter assay. Data are presented as the mean of triplicate replications. S.D. is indicated by error bars. ∗∗P<0.001
versus HEK293/NNMT cells transfected with wild-type D3 construct.
reporter assay revealed that the mutation of SP1-binding ele-
mentscauseda4-foldreductionofMMP-2promoteractivity
in HEK293/NNMT cells (Figure 7(b)). These results suggest
that the SP1-binding region of MMP-2 promoter plays a
crucial role for NNMT-mediated MMP-2 expression. To
study whether SP1 plays a role in NNMT-mediated MMP-2
expression, siRNA speciﬁc to SP1 gene was used. As revealed
in Figure 8(a), the expression of MMP-2 was markedly
reduced by the treatment of SP1 siRNA in HEK293/NNMT,
786O. and Caki-1 cells. Moreover, mithramycin, which has
been shown to prevent SP1 binding to gene promoters
[51], was used to suppress SP1 transcriptional activity. The
results showed that treating with mithramycin apparently
suppressed the expression of MMP-2 in HEK293/NNMT,
786O,andCaki-1cells(Figure 8(b)).ItsuggeststhatSP1isan
important factor for MMP-2 expression activated by NNMT.
Furthermore, CHIP assay was carried out to inves-
tigate the role of PI3K/AKT pathway in SP1-binding to
MMP-2 promoter. The results demonstrated a 2.9-fold
increase of SP1 association to the SP1 binding elements
of the MMP-2 promoter in HEK293/NNMT cells com-
pared with HEK293/vector cells (Figure 9). Treating with
LY294002 or AKT inhibitor IV remarkably reduced the
association between SP1 and the MMP-2 promoter in
HEK293/NNMT cells (Figure 9). These results stronglyJournal of Oncology 11
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Figure 8: Importance of SP1 in MMP-2 expression induced by NNMT. (a) Eﬀects of SP1 siRNA on the expression of MMP-2 and SP1. Cells
were transfected with 40μmol/L of SP1 siRNA or control siRNA, and Q-PCR was performed to determine the expression levels of NNMT
and MMP-2. Data are presented as the mean of triplicate replications. S.D. is indicated by error bars. ∗P<0.05; ∗∗P<0.001 versus control
cells. (b) Eﬀects of SP1 inhibitor, mithramycin, on the expression of MMP-2. Cells were treated with 12.5 or 25nmol/L of mithramycin
for 18h, and the expression levels of MMP-2 were examined by Q-PCR. Data are presented as the mean of triplicate replications. S.D. is
indicated by error bars. ∗P<0.05; ∗∗P<0.001 versus control cells.
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Figure 9: Role of PI3K/AKT pathway in the binding of SP1
to MMP-2 promoter. HEK293/NNMT cells were treated with or
without 5μmol/L of LY294002 or 1μmol/L of AKT inhibitor IV for
18h, and the association of SP1 on the SP1 binding elements of the
MMP-2 promoter was determined by CHIP assay. Rabbit IgG was
used as the negative control and 4% input as positive control.
implicate that PI3K/AKT/SP1 pathway participates in MMP-
2 promoter activation induced by NNMT expression.
10. Involvement of MMP-2 in
NNMT-MediatedCellInvasiveness
Whether NNMT-mediated MMP-2 expression causes cell
invasion was investigated by matrigel invasion assay. As
Figure 10(a) shows, HEK293/NNMT cells exhibited a higher
invasive activity than HEK293/vector cells. To examine
the role of MMP-2 in NNMT-mediated cell invasiveness,
the MMP-2-neutralizing antibody or MMP-2 inhibitor
(OA-Hy) were applied to block the activity of MMP-2.
The results of matrigel invasion assay indicated that the
inhibition of MMP-2 activity signiﬁcantly suppressed the
invasive activity in HEK293/NNMT cells (Figure 10(b)).
Additionally, the eﬀects of NNMT siRNA on the invasiveness
of ccRCC cell lines were studied. The results showed
that treating with NNMT siRNA resulted in about 70%
reduction of the invasive activity in 786O and Caki-1 cells
(Figure 10(c)). Moreover, NNMT siRNA-suppressed inva-
siveness was restored by the treatment of MMP-2 active pro-
tein (Figure 10(c)). These results indicate that MMP-2 activ-
ity is required for the invasiveness of NNMT-overexpressing
cells.
11. Effects of NNMT shRNA on Tumor
GrowthandMetastasisof
ccRCC Cells in NOD-SCID Mice
Whether the reduced NNMT expression inhibits the tumor
growth and metastasis of ccRCC cells was investigated by
the experiment of NOD-SCID mice. 786O cells with stably
expressing NNMT or luciferase shRNA were generated by
using puromycin selection after infected with the lentivirus12 Journal of Oncology
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Figure 10: Enhancement of cell invasiveness by NNMT via MMP-2. (a) Matrigel invasion assay was used to analyze the invasive activity.
HEK293/vectorandHEK293/NNMTcellswereseededintothematrigel-coatedchamberandincubatedat37◦Cfor24h.(b)EﬀectsofMMP-
2-neutralizing antibody or MMP-2 inhibitor OA-Hy on the invasive activity of HEK293/NNMT cells were examined. Data are presented as
the mean of triplicate replications. S.D. is indicated by error bars. ∗P<0.05; ∗∗P<0.001 versus untreated HEK293/NNMT cells. (c) 786O
and Caki-1 cells were transfected with 40μmol/L of NNMT siRNA for 24h and then incubated with or without 20ng of MMP-2 protein in
matrigel-coated chamber for another 24h. Data presented are the mean of triplicate replications. S.D. is indicated by error bars. ∗∗P<0.001
versus control cells.
containing NNMT or luciferase shRNA. As demonstrated
by western blot analysis, NNMT shRNA markedly sup-
pressed about 90% of NNMT and 70% of MMP-2 expres-
sion in 786O cells (Figure 11(a)) .T h ei n v a s i v ea c t i v i t yo f
786O/NNMT shRNA was reduced to 25% of that of 786O/
control shRNA (Figure 11(b)). By subcutaneous injection
into the hind limb of NOD-SCID mice, 786O/NNMT
shRNA cells developed less tumor mass than 786O/luciferase
shRNA cells in NOD-SCID mice (Figure 11(c)). The lung
metastatic activity of 786O cells with or without NNMT
knockdown was further studied by using intravenous injec-
tion into lateral tail vein of NOD-SCID mice. As shownJournal of Oncology 13
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Figure 11: Eﬀects of NNMT shRNA on the growth and lung metastasis of ccRCC cells in NOD-SCID mice. Western blot analysis (a) and
matrigel invasion assay (b) were performed to examine NNMT and MMP-2 expression and invasive activities of 786O/NNMT shRNA and
786O/control shRNA cells. Actin was used as loading control. (c) 4 × 106 of 786O/NNMT shRNA or 786O/luciferase shRNA cells were s.c.
injected into the hind limb of NOD-SCID mice (n = 6). Tumor volume was measured every three days. Data are presented as the mean of
triplicate replications. S.D. is indicated by error bars. ∗∗P<0.001 versus control cells. (d) 1 × 106 of cells in 200μL of serum-free DMEM
mediumwere intravenously injected intothe lateral tailvein ofNOD-SCID mice (n = 6).After 6 weeks of injection, the mice were sacriﬁced,
and the metastatic nodules of lungs were counted. Data are presented as the mean ±SD. ∗P<0.05 versus control cells.
in Figure 11(d), the lung metastasis of 786O cells was
signiﬁcantly suppressed 90% by NNMT shRNA as compared
tocontrolshRNA.TheseresultsindicatethatsilencedNNMT
expression inhibits tumor growth and lung metastasis of
ccRCC cells.
12. Conclusions
Gene expression proﬁling is one of important methods for
studying multifactor diseases and for indentifying the poten-
tial biomarkers as the target genes for cancer chemotherapy.14 Journal of Oncology
Weapplythefull-lengthenrichedcDNAmethodtoconstruct
the ﬁrst full-length enriched cDNA libraries of ccRCC and
normal kidney tissues. The advantages of present method
are (1) the number of upregulated or downregulated genes
is obtained more precisely than that of microarray, and (2)
the mutations such as point mutation, insertion or deletion,
and SNP sites can be identiﬁed from the sequencing of full-
length enriched cDNA libraries.
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